More specifically, Betancur et al. showed that a large repertoire of active constituent enhancers, located within the two CD47 SEs, modulate CD47 expression in cancer cell types, and that impairment of CD47 SEs reduced CD47 gene expression in BC [37]. Here, CD47 is linked to cancer.